Monogram Technologies Inc.
6.00+0.00 (+0%)
Oct 6, 4:00:01 PM EDT · NasdaqCM · MGRM · USD
Key Stats
Market Cap
243.79MP/E (TTM)
-Basic EPS (TTM)
-0.54Dividend Yield
0%Recent Filings
8-K
Merger completes, delisting follows
Monogram Technologies completed its merger with Zimmer Biomet on October 7, 2025, becoming a wholly-owned subsidiary and delisting from Nasdaq. Shareholders received $4.04 cash per common share plus non-transferable CVRs potentially worth up to $12.37 based on milestones like FDA clearance by 2027 and revenue targets through 2030. This bolsters Zimmer Biomet's robotics portfolio with Monogram's AI-driven tech, yet integration risks loom large. Deal closed post-HSR expiration.
8-K
Merger Vote Approved
Monogram Technologies' stockholders approved the merger with Zimmer Biomet on September 30, 2025, with 63.95% of outstanding shares voting yes on the July 11 agreement, as amended August 27. The deal, merging Monogram into a Zimmer Biomet subsidiary, awaits HSR antitrust clearance and other conditions. Closing is eyed for late 2025. Regulatory hurdles could delay or derail it.
8-K
Merger review extended
Monogram Technologies withdrew and refiled its HSR Act notification on September 4, 2025, restarting the antitrust waiting period to October 6 and extending regulatory scrutiny of its merger with Zimmer Biomet. This standard step aids FTC review while the deal, announced July 11, awaits shareholder approval and other conditions. Closure remains targeted for late 2025. Delays risk prolonged uncertainty.
8-K
Monogram solicits acquisition votes
Monogram Technologies kicked off its stockholder outreach on August 29, 2025, with texts and emails urging votes for the Zimmer Biomet acquisition at the September 30 special meeting. The board pushes approval of the merger agreement and a potential adjournment option, highlighting the deal's background and rationale in the proxy statement. Every vote counts. Investors should review SEC filings for full details on this pivotal transaction.
8-K
Merger amendment addresses SEC note
Monogram Technologies amended its merger agreement with Zimmer Biomet on August 27, 2025, tweaking the 'Permitted Transfer' definition in the CVR agreement to address an SEC comment. This minor adjustment keeps the planned acquisition on track, with no changes to the core merger terms. Deal closes as scheduled.
IPO
Employees
Sector
Industry
AMIX
Autonomix Medical, Inc.
1.09-0.04
MBOT
Microbot Medical Inc.
2.19-0.20
NMTC
NeuroOne Medical Technologies C
0.82-0.02
OFIX
Orthofix Medical Inc.
16.02-0.06
PRCT
PROCEPT BioRobotics Corporation
36.95+0.60
RBOT
Vicarious Surgical Inc.
5.75-0.10
RMTG
Regenerative Medical Technology
0.05-0.02
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00
SYK
Stryker Corporation
375.93-7.79
ZBH
Zimmer Biomet Holdings, Inc.
101.14-1.98